$tr2['classname']

肺癌

$tr2['classname']

乳腺癌

$tr2['classname']

结直肠癌

$tr2['classname']

前列腺癌

$tr2['classname']

甲状腺癌

$tr2['classname']

宫颈癌

$tr2['classname']

胃癌

$tr2['classname']

肝癌

$tr2['classname']

胆囊癌

$tr2['classname']

卵巢癌

$tr2['classname']

食管癌

$tr2['classname']

胰腺癌

$tr2['classname']

膀胱癌

$tr2['classname']

淋巴瘤

$tr2['classname']

子宫内膜癌

$tr2['classname']

肾癌

$tr2['classname']

罕见肿瘤

首页 > TAG信息列表 > 达攸同

|

信迪利单抗|最新研究

信达生物在ESMO主题大会公布ORIENT-31（达伯舒联合达攸同及化疗）用

贝伐珠单抗(达攸同)|上市信息

信达生物宣布达攸同（贝伐珠单抗注射液）新增两项适应症获批，治疗卵巢